LETTER TO THE EDITOR

Hepatocellular carcinoma screening among hepatitis B-infected Asian Americans

To the Editor:

Sarkar et al. concluded from a retrospective series of 1870 HBsAg-positive Asians living in California that hepatocellular carcinoma (HCC) screening improved survival [1]. However, the results from the two randomized controlled trials in the hepatitis B-infected population are conflicting, and the beneficial effects of HCC screening remains a matter of debate [2,3]. Moreover, previous observational studies also concluded that screening improved survival despite raw data showed that screened patients died younger than nonscreened patients (lead time bias) [4].

Accordingly, the authors must provide: a) the Kaplan–Meier curves for mortality from all causes and for mortality from HCC in the 1646 active patients (Fig. 3 only provided survival curve in the 51 patients with HCC) comparing screened and unscreened patients; b) the mean age at death and patients’ characteristics for both groups.

Last, screening is a complex issue which necessitates a national programme with well-defined surveillance tests and quality controls. Screening advocates must understand that patients deserve evidence-based medicine and that poor evidence is a leading cause of poor compliance, as observed in this retrospective series, a situation precluding efficiency.

A. Braillon

Public Health, Amiens France
E-mail: braillon.alain@gmail.com

REFERENCES